10 November 2025

Three *Sofdra*® posters presented at dermatology conferences

Philadelphia PA and Phoenix AZ, 10 November 2025: Commercial dermatology company, Botanix Pharmaceuticals Ltd (ABN 70 009 109 755) (ASX:BOT, "Botanix" or "the Company"), is proud to announce acceptance and exhibition of three *Sofdra*® (sofpironium) posters at leading dermatology continuing medical education (CME) conferences. Interest in the science of *Sofdra* remains high, and CME is a trusted source of information.

The importance of healthcare professionals identifying and engaging with primary axillary hyperhidrosis patients has been underscored in a Botanix scientific poster exhibited at the Fall Clinical Dermatology Conference, 23–26 October 2025, and the Society of Dermatology Physician Associates (SDPA), 5–9 November 2025. Essential guidelines for clinicians by clinicians are presented in the poster titled, "*Clinical Best Practices and Insights Toward Improving Recognition, Diagnosis, and Treatment of Primary Axillary Hyperhidrosis (PAH)*."

An additional Botanix scientific poster, *"Sofpironium Targets M3 Receptors and Results in Early Clinical Meaningful Improvement in Primary Axillary Hyperhidrosis (PAH),"* focusing on sofpironium's unique mechanism of action and the results of its robust clinical trials, was also accepted by the Fall Clinical Dermatology Conference, one of the leading CME dermatology conferences in the US, with more than 1,200 attendees.

Authors of the Company's scientific posters are prominent faculty members of leading conferences who can be expected to raise awareness of poster content by integrating it into their presentations.

FALLCLINICAL DERMATOLOGY CONFERENCE®

Fall Clinical Dermatology Conference

Two scientific posters accepted:

Society of Dermatology Physician Associates

One scientific poster accepted:





About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology company based in Philadelphia and Phoenix (US), which has received FDA approval for its lead product *Sofdra* for the treatment of primary axillary hyperhidrosis. *Sofdra* is the first and only new chemical entity approved by FDA to treat primary axillary hyperhidrosis and presents a novel safe and effective solution for patients who have lacked treatment options for this socially challenging medical condition.

To learn more please visit: http://www.botanixpharma.com/

For more information, please contact:

General enquiries
Corporate Communications
Botanix Pharmaceuticals
P: +61 8 6555 2945
investors@botanixpharma.com

Investor enquiries
Hannah Howlett
WE Communications
P: +61 450 648 064
hhowlett@we-worldwide.com

Media enquiries
Haley Chartres
H^CK
P: +61 423 139 163
haley@hck.digital

***Sofdra* Important Safety Information & Indication**

Indication

Sofdra (sofpironium) topical gel, 12.45% is a prescription anticholinergic medicine used on the skin (topical) to treat excessive underarm sweating (primary axillary hyperhidrosis) in adults and children 9 years of age and older.

IMPORTANT SAFETY INFORMATION

***Sofdra* is for use on the skin in the underarm area only. Wash your hands right away after you apply *Sofdra*. Do not touch your underarms after applying *Sofdra*. *Sofdra* is flammable. Avoid heat and flame while applying *Sofdra*.**

Who should not use *Sofdra*?

Do not use *Sofdra* if you have certain medical conditions that can be made worse by taking an anticholinergic medicine such as glaucoma, severe ulcerative colitis (UC) or certain other serious bowel problems associated with severe UC, myasthenia gravis, and Sjogren's syndrome.

What should I tell my healthcare provider before using *Sofdra*?

- **Tell your healthcare provider about all of your medical conditions,** including bladder or kidney problems, problems passing urine, if you are pregnant or breastfeeding, or plan to become pregnant or breastfeed. It is not known if *Sofdra* will harm your unborn baby or pass into your breast milk.
- **Tell your healthcare provider about all the medicines you take,** including prescription and over-the-counter medicines, especially any anticholinergic medicines.

What are possible side effects of *Sofdra*?

Serious side effects may include:

- **Blurred vision.** Stop using *Sofdra*, call your healthcare provider right away, and do not drive or operate machinery or do hazardous work until your vision is clear.
- **New or worsened urinary retention.** Stop using *Sofdra* and call your healthcare provider right away if you experience difficulty urinating, urinating frequently, urination in a weak stream or drips, full bladder or difficulty emptying your bladder.

The most common side effects of *Sofdra* include dry mouth; blurred vision; pain, redness, swelling, itching, and irritation in the underarm area; dilation of the pupils of your eyes (mydriasis); and problems with urination. These are not all of the possible side effects of *Sofdra*. Call your doctor for medical advice about side effects.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Botanix at 1-866-763-6337.

Keep *Sofdra* and all medicines out of the reach of children.